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Summary.-Since 1975, 191 patients with Hodgkin's disease have been treated with
a combination of chlorambucil, vinblastine, procarbazine and prednisolone
(ChlVPP).
Complete remission rates were 73% for previously untreated patients, 910% for
patients previously treated with radiotherapy and 55%0 for patients previously
treated with chemotherapy.
In 59 patients with advanced disease who received no other treatment, a 5-year
survival rate of 66°, was comparable with that achieved by more toxic mustine-
containing combinations. Ch1VPP has few side effects, is easily given to outpatients,
and can be combined with elective radiotherapy in selected patients.
SINCE ITS INTRODUCTION in 1964, the
MOPP combination of mustine, vin-
cristine, procarbazine and prednisone (De
Vita et al., 1970) has radically changed the
treatment of advanced Hodgkin's disease,
which is now chemocurable in many cases
(De Vita et al., 1980). Ifvinblastine is sub-
tituted for vincristine (MVPP, McElwain
et al., 1973) the combination is less
neurotoxic than MOPP and gives com-
parable remission and survival rates
(Sutcliffe et al., 1978). In 1977 we reported
the use of ChlVPP (McElwain et al., 1977)
in which chlorambucil replaced mustine in
the MVPP combination. This combination
was designed to reduce the nausea,
vomiting and risk ofphlebitis produced by
mustine and was shown by us to do so
(Kaye et al., 1979). Our early experience
with Ch1VPP suggested that it produced
complete remission and survival rates
similar to MOPP and MVPP. Stout &
Todd (1979) later reported less favourable
results using a similar regimen, but the
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mean age of their patients was high, and
there was an excess of other poor prog-
nostic features. We now report 5 years'
experience with the use of Ch1VPP in 191
patients.
PATIENTS AND METHODS
Since 1975, 191 patients requiring chemo-
therapy for Hodgkin's disease (HD) have
received ChlVPP. The series is unselected.
No patients referred to our unit received
MOPP, MVPP or any other first-line regimen
during this period, though patients who had
previously received MOPP or MVPP as
first-line treatment received ChlVPP as
treatment for relapsed disease. Ages ranged
from 3 to 76 years, median 27, mean 29.
Histological classification was by the criteria
of Lukes & Butler (1966), staging was by the
Ann Arbor system (Carbone et al., 1971),
either pathological with laparotomy (Gazet,
1973) or clinical (McElwain et al., 1973).
Details of the 139 patients who had received
no previous treatment before ChlVPP are
shown in Tables I and II.8P. J. DADY ET AL.
Survival was measured from the start of
chemotherapy with ChlVPP. Our main
objective in this report is to present the
effect of ChlVPP in HD; therefore patients
receiving elective radiotherapy after ChlVPP
chemotherapy (vide infra) and achieving
only partial remission before radiotherapy
were classified as partial remitters. In
evaluation of disease-free survival, only
those patients who achieved complete re-
mission on chemotherapy alone were deemed
to have had disease-free survival; patients
who only attained complete remission after
subsequent radiotherapy were excluded from
this analysis. Overall survival and disease-
free survival curves were plotted using the
life-table method. The logrank method was
used to test for significant differences
between these curves (Peto et al., 1977). P
values for differences in complete remission
rates were derived using a 2 x 2 contingency
table; where no P value is given, differences
are not significant.
Treatment
ChlVPP is:
Days 1-14 Chlorambucil 6 mg/m2/day
inclusive orally (Not exceeding 10
mg/day)
Procarbazine 100 mg/m2/day
orally (not exceeding 150
mg/day)
Prednisolone 40 mg/day
orally*
Days 1 & 8 Vinblastine 6 mg/M2 i.v. (not
exceeding 10 mg per single
dose)
Each course of treatment is followed by a
2-week gap. Full details of administration
and toxicity have been published previously
(McElwain et al., 1977; Kaye et al., 1979).
Patients treated with ChlVPP alone.-These
are shown in Table I. There were 59 patients,
47 of whom had Stage IIIB or IV disease.
The others were as shown, and most had
poor prognostic features, either bulky disease,
"B" symptoms or multiple disease sites.
Combined-modality treatment.-A group of
80 previously untreated patients, shown in
Table II, who would conventionally have
been treated with radiotherapy alone, but
* The standard adult dose irrespective of patient
size. In children, doses were given on the basis of
25 mg/M2.
in whom there was a high probability of this
treatment failing to cure, were electively
treated with 6 cycles of ChlVPP before
radiotherapy. As reported in our previous
publications, the combined-modality group
included adult patients with lymphocyte-
depleted histology, Stage II disease with
"bulky" mediastinum (transverse diameter
exceeding one third of the transverse dia-
meter of the chest at the same level on
X-ray), those with more than 3 nodal areas
involved above the diaphragm, pathological
Stage IIIA disease with splenic involvement
and some patients in Stage IIIB. Radio-
therapy started 6 weeks after the last course
of chemotherapy. The extended field
("mantle", "inverted Y" or "total nodal")
appropriate to the extent of the disease at
presentation was treated with 35 Gy mid-
plane dose in 20 fractions per 4-week course.
Details of the rationale for this combined
modality approach have been published
elsewhere (Peckham & McElwain, 1977).
Chitldren.-All children under the age of 14
years received ChlVPP, irrespective of stage.
There were 27 such patients in this series.
Those with Stage I or II disease received
additional radiotherapy to involved fields
only; those with Stage III and IV disease
received chemotherapy alone. It is our
policy not to use laparotomy and splenec-
tomy in staging children, in view of the risk
of subsequent infection, nor to treat with
total nodal radiation, to avoid the risk of
preventing normal spinal growth (Smith
et al., 1977). Chemotherapy in clinically
staged children lessens these risks, while
maintaining an acceptable anti-tumour effect.
TABLE I.-Patients treated wiith ChlVPP
alone
Stage
IIA bulky mediastinum* or > 3 sites
involved above diaphragm
IIB as above
IIIA (all children)
IIIA splenic involvement
IIIB
IVA
IVB
Total
No.
2
2
3
5
5
18
24
59
* Ratio of mediastinal width measured at the
widest point to thoracic transverse diameter
measured at the same level > 1 :3 on a 6 ft. p.a.
chest film.
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TABLE II. Treatment modality with indications: 139 previously untreated patients
Category*
Stage IIA Bulky mediastinum
> 3 sites involved
Stage IIIA Splenic involvement
IIIB
IVA
IVB
Lymphocyte depleted histology
Children < 14 years
Total patients*
ChlVPP only
4
3
5
5
18
24
3
8
59
No. treated
Combined modality
15
16
26
21
0
0
16
80
* Several patients fall into moie than one category.
TABLE III.-Complete remission by treatment, age, sex, symptoms and histology
No. of patients
Complete remissions
No. %
No previous treatment
ChlVPP alone
Combined modality
Previous treatment
Radiotherapy only
Chemotherapy +radiotherapy
Age in years
<40
>40
Sex
Male
Female
Symptoms
A
B
Histology
Lymphocyte-predominant
Nodular sclerosis
Mixed cellularity
Lymphocyte-depleted
RESULTS
Remission rates
Complete remission was defined as
complete disappearance of all clinically
detectable Hodgkin's disease, with resolu-
tion of all radiological and laboratory
evidence suggesting active HD. Partial
remission was defined as >50%0 reduction
in the diameter of lesions measured in 2
planes at right angles, and abolition of all
HD symptoms.
The complete remission rate for 191
patients was 74%0. It was 73% for
previously untreated patients and 910% for
patients who had relapsed after treatment
with radiotherapy alone. Twenty patients
who had received previous chemotherapy
(usually MVPP) had a complete remission
rate of only 55%. Details are given in
Table III. Also shown in Table III
are complete-remission rates by treatment
programme, age, sex, symptoms and
histology. Young female asymptomatic
patients were more likely to achieve
complete remission than old male sympto-
matic patients, though these differences
were not statistically significant. Patients
with lymphocyte-depleted disease had
only a 57% rate of complete remission,
and those with lymphocyte-predominant,
62%, but both groups were small. The
larger groups of patients with nodular
59
80
32
20
154
37
129
62
102
89
13
125
46
7
43
59
29
11
117
25
94
48
79
63
8
100
30
4
73
74
91
55
76
68
73
77
77
71
62
80
65
57
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TABLE IV.-Complete remission by stage
Clinically staged
Complete remission
No. No. %
4 3 75
12 9 75
8 5 63
6 4 68
5 4 80
11 7 64
23 18 78
69 50 72
Pathologically staged
I-
No.
1
14
13
41
26
13
14
122
Complete remission
C -
No. %
1 100
9 64
9 69
36 88
21 81
10 77
6 43
92 74
Total
% Complete
No. remissions
5 80
26 69
21 67
47 85
31 81
24 71
37 65
191 94
sclerosis and mixed-cellularity disease had
80% and 65% complete-remission rates,
respectively, which were significantly
different (P < 0.05). The effect of stage on
complete remission is shown in Table IV;
the higher rate for Stage III than for
Stage II is significant (P < 0.05). This
is accounted for by the selected nature
of the Stage II patients who received
chemotherapy, 19 of whom had bulky
mediastinal disease. In half of these,
despite complete disappearance of tumour
at all other sites, the mediastinal
contour did not return to normal, as is
often the case with disease at this site.
Thus they could not technically be con-
sidered as having achieved complete
remission before elective radiotherapy was
given. No difference was found between
complete-remission rates of patients
staged clinically as those staged
pathologically.
Survival
Patients are still being entered into this
study. The newest of these entries cannot
have relapsed or died yet. For this reason,
we provide overall and disease-free sur-
vival for the first 70 patients whom we
reported in our original ChlVPP paper
(McElwain et al., 1977), who have been
followed for more than 4 years, as well as
for the entire group of patients.
First 70 patients.-These patients have
now been followed from 48 to 65 months
from starting chemotherapy. Thirty-six of
these received no previous treatment
before ChlVPP. Sixteen were treated with
Ch1VPP alone (Stage IIIA (1), IIIB (1),
IVA (6). IVB (8)) and 20 with elective
radiotherapy after ChlVPP (Stage IA (1),
IIA (6). IIB (4), IIIA (4), and IIIB (5). Of
the 34 previously treated patients, 22 had
relapsed after previous radiotherapy and
12 had received previous chemotherapy,
usually MVPP or MOPP. Figs 1 & 2 show
the survival and disease-free survival for
these 4 groups of patients. At 5 years the
patients who had received no previous
treatment have an actuarial survival rate
of 78% (68%, ChlVPP only; 95%, com-
bined modality). Previously irradiated
patients have a 72% actuarial survival
rate, but the group of patients with
previous chemotherapy have a 4-year
overall survival of only 34%, and the
figure for 5 years is even worse (25%).
Although the number of patients is small,
only one of these patients has reached 4
years without relapsing. The differences in
overall and disease-free survival between
the group previously treated with chemo-
therapy and the other 3 groups are
significant (P < 0 002).
All patients. The overall and disease-
free survival ofall 191 patients (Figs 4 & 5)
show a pattern similar to that of the first
70 patients, with an actuarial 5-year
survival rate of 66% in patients receiving
no other treatment. As with the first 70
patients, the group treated with chemo-
therapy on the relapse from primary
treatment with radiotherapy have done
particularly well, with a projected survival
of 76% at 5 years. The prognosis for those
patients who relapsed after previous
Stage
IA
IIA
IIB
IIIA
IIIB
IVA
IVB
Total
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FIG. 1.-First 70 patients. Survival related
to treatment group. 4-year and 5-year
survivors are indicated.
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FIG. 4.-All patients. Disease-free survival of
142 patients achieving complete remission
by treatment group.
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FIa. 2. First 70 patients. Disease-free
survival of 54 patients achieving com-
plete remission, related to treatment group.
100 -m:
80 L ... -- 1 8 0--'I. X r / Prev. RT (32)
16 2.. Comb. modality (80)
Chl VPP only (59)
'40- 5_
3 1
20 L Prev.CTtRT (20) p<0.002
6 12 18 24 30 36 42 48 54 60 66
Months
FIG. 3. All patients. Survival of 191 patients
by treatment group.
chemotherapy remains poor (P < 0.002);
they have a low rate ofcomplete remission
and a high relapse (P < 0.02).
Not surprisingly, patients achieving
complete remission live longer than those
who do not (P < 0 001) (Fig. 5). If relapse
does not occur in the first year (Fig. 6)
actuarial survival at 5 years is 90%, as
against 45% for patients relapsing during
FIG. 5.-All patients. Overall survival and
survival by remission status.
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FIG. 6. 142 patients with initial remission.
Survival by remission status at 1 year.
the first year (P < 0-0001). The tendency to
relapse is greatest in the first 2 years of
remission; thereafter the rate of relapse
slows markedly.
In considering the effects of age,
symptoms, histology and stage, we have
excluded the 20 patients previously
treated with chemotherapy before
ChlVPP. The probability of overall sur-
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14 yrs (27)
14 - 30 yrs (86)
6 3 30 - 40 yrs (21)
' * * - 40 yrs (31)
TABLE V.-Effect of stage on overal
survival
Stage
IIA
JIB
IIIA
IIIB
IVA
IVB
% survival
at 4 years
75
46
83
62
83
65
I I I
6 12 18 24 30 36 42 48 54 60 66
Months
FiG. 7. All patients. Probability of survival
by age group at start of treatment.
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FIG. 8. All patients. Probability of survival
by symptomatic status. A no symptoms;
B significant fever and/or sweating and/
or weight loss.
vival is related to age (Fig. 7). Fig. 8
compares the overall survival of patients
with symptomatic disease (B) with that of
asymptomatic patients (A) which is pro-
jected at 61% and 80%, respectively, at 5
years. When histology is considered,
nodular sclerosis is associated with a
higher rate of complete remission than
mixed cellularity, and for about 2 years
overall survival is better, but at 5 years
the actuarial survival rates are respec-
tively 770o and 66%. Table V shows the
probability of survival by stage. The
strong influence of "B" symptoms is
evident for each stage.
DISCUSSION
Untreated Hodgkin's disease is fatal,
and HD treated with inadequate chemo-
therapy is usually fatal. Properly treated
it is often curable. MOPP or MVPP are
highly effective chemotherapeutic regi-
mens, and proposed alterations must be
compared with them to ensure that
patients are not exposed to inadequate
treatment. Hence this, our third, review of
Ch1VPP.
If the combined-modality group is
excluded, a complete remission rate for
untreated patients with advanced disease
of 73%, and a rate of 740o for all patients,
are similar to those reported for MOPP
(De Vita et al., 1980) and MVPP (Sutcliffe
et al., 1978). Five-year overall and disease-
TABLE VI. Comparison of ChlVPP, MVPP and MOPP
ChlVPP MVPP*
No previous treatment (chiemotherapy only)
Complete remission (o)
5-year survival (%)
5-year disease-free survival (0o)
(remitters only)
Previous radiotherapy
Complete remission (%)
5-year survival (%)
5-year disease-free survival (%)
(remitters only)
* Sutcliffe et al., 1978.
t De Vita et al., 1980.
73
66
64
91
76
75
76
65
70
90
86
83
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free survivals indicate that ChlVPP is no
less effective than the more toxic regimens.
For example, Sutcliffe et al. (1978) found a
5-year survival of 65% in 49 patients with
advanced disease treated with MVPP
alone. In our 59 equivalent patients the
figure is 66%. Five-year disease-free sur-
vival for patients achieving complete
remission was 70% in the MVPP series and
is 64% in this series for patients treated
with ChlVPP only (Fig. 2). A tabulated
comparison of our data with those for
MVPP and MOPP is given in Table VI,
and shows a close similarity between
remission rates and survival for the 3
treatments. It also shows clearly that
patients relapsing after primary treatment
with radiotherapy may be reclaimed.
A low proportion of the previously
irradiated patients had "B" symptoms or
large-volume disease, suggesting that regu-
lar outpatient supervision of patients who
had been previously irradiated enabled
the detection of recurrent disease before
it became extensive or symptomatic. In
contrast to De Vita, we found the
complete-remission rate for patients with
nodular sclerosis to be higher than for
patients with mixed cellularity, but as in
the MOPP series, those with nodular
sclerosis had a higher rate of relapse.
Seventy-eight per cent of the previously
irradiated patients had nodular sclerosis,
compared with 650/a for all patients.
Actuarial 5-year survival for thosepatients
where "salvage" was attempted after
earlier chemotherapy was 25%, a figure
compounded from a low rate of complete
remission and a high rate of relapse in
those who did achieve complete remission.
The disease in these patients did not show
any excess of the "bad" prognostic
features, neither were these patients
older than the others. Over 8000 had
been previously treated with MOPP or
MVPP, and there is likely to be cross-
resistance between these combinations
and ChlVPP. Our experience with a "non-
cross-resistant" regimen (ABVD) in re-
lapsed patients does not indicate any
better results (unpublished data), which
suggests that the poor results for "salvage"
chemotherapy have more to do with
intrinsic resistance of the tumour than
inadequacy of the "salvage" chemo-
therapy (in this case ChlVPP).
Half of the previously untreated Stage
II patients had bulky mediastinal involve-
ment. These had a lower rate of complete
remission than other patients with Stage
II disease, and a greater tendency to
intrathoracic relapse, which suggests that
large-volume disease in the mediastinum
had not been completely eradicated. The
tendency for large-volume mediastinal
nodular sclerosis to recur locally after
radiotherapy has been extensively report-
ed (Goodman & Hellman, 1978; Timothy
et al., 1978). It has been suggested that
the high recurrence rate in Stage II
disease treated with radiotherapy alone
could be due to occult disease in the
abdomen, especially in the spleen (Ains-
berg, 1978). Fifty-five per cent of our
Stage II patients had undergone laparo-
tomy and splenectomy; the complete-
remission rates of these and the clinically
staged patients were similar (67 and
700 %) as was the disease-free survival.
Either occult disease was not present in
the abdomen or it was eradicated by
chemotherapy. Where large-volume HD
occurs in the mediastinum, our policy is
still to use ChlVPP before irradiation in
order to reduce the tumour mass. ChlVPP
does not compromise subsequent elective
radiotherapy. A fuller account of our
experience with early-stage HD involving
the mediastinum has been published
elsewhere (Velentjas et al., 1980).
In this analysis the correlation between
age and overall survival is highly signi-
ficant; however the pattern of relapse,
especially in the 14-30-year age group,
indicates that in future analyses this
relationship may not attain the same
significance. The 91% overall survival at
5 years for children under the age of 14
encourages us to continue our present
treatment policyinthesepatients. Patients
over the age of 40 years have a (non-
significant) lower rate ofcomplete response
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than younger patients. There is no evi-
dence that they are less able to tolerate
chemotherapy; a small sub-group of
patients over the age of 70 years received
on average the same amount of Ch1VPP
as younger patients. The bad prognostic
implications of "B" symptoms are well
recognized. Our data suggest that this is
due to the lower rate of complete remis-
sion in symptomatic patients, as the
relapse rates for symptomatic and asymp-
tomatic patients are similar. It would
seem that, irrespective of stage, the prob-
ability of survival at 4 years is better for
asymptomatic patients. For example, the
patient with Stage IVA disease is more
likely to survive 4 years than the patient
with Stage JIB or IIIB disease. It should
of course be remembered that "early-
stage" patients selected for chemotherapy
have disease which we consider to have
unfavourable prognostic features. It is
unlikely that this observation would hold
ifall "early-stage" patients were analysed,
including those treated with radiotherapy
alone.
In 1973, Frei and others advocated a
combination of chemotherapy followed
by irradiation ofinvolved sites. Since then
there have been several reports of com-
bined-modality treatment with various
drug combinations and radiotherapy dos-
ages. Bonadonna et al. (1977) reported
65.7% overall survival at 3 years, using
6 courses of MOPP and 30-35 Gy to sites
of nodal disease. Hoppe et al. (1979) gave
40-44 Gy total lymphoid irradiation in
divided doses, alternating with chemo-
therapy; at 45 months overall survival
was 84%. As we report here, of the 20
patients in our combined-modality group
who could have survived 5 or more years,
19 (95%o) have done so, which confirms
that this approach is effective in patients
in whom treatment with radiotherapy
alone is unlikely to prove permanently
effective. It is not pertinent for this publi-
cation to comment further on combined-
modality treatment, except to note that
elective radiotherapy can be given with
relative ease after ChlVPP treatment.
Three patients in this series have so
far developed second tumours: one, who
relapsed after radiotherapy, was treated
with ChlVPP, achieved complete remis-
sion, but then died of histologically pro-
ven, poorly differentiated diffuse lympho-
cytic lymphoma; a second patient simil-
arly treated has developed a malignant
melanoma; and a third patient in the
group treated electively with combined-
modality therapy had died of acute
myeloblastic leukaemia. Longer follow-up
is required to assess the excess risk of
second malignancy from combined-
modality treatment.
We have previously reported (McElwain
et al., 1977; Kaye et al., 1979) that ChlVPP
is remarkably free of toxic side-effects,
notably nausea and vomiting, and con-
tinuing experience confirms this. Less
than 10% ofpatients vomit, and only one-
fifth have any nausea. Routine anti-
emetics are not given. Alopecia is never
encountered, and mild peripheral neuro-
pathy has only been observed in a handful
of older patients. We continue to be able
to administer more than 950 of the
calculated dose of all the drugs in a full
programme oftreatment. The combination
is conveniently administered to out-
patients and treatment-related complica-
tions requiring hospital admission are
rare. This review of our results does not
show ChlVPP to be any less effective than
conventional drug combinations, andunder
these circumstances it remains the first-
line chemotherapy for HD at this hospital.
However, although it is less toxic to the
patient, its anti-tumour effect is no
greater than that of other first-line com-
binations. This underlines the need to
develop more effective (and probably
more toxic) combinations, and to define
those patients needing to receive them.
Both these objectives are in sight, and the
second may be within reach, since this
study, like many others, clearly defines
patients with clinical features that are
associated with failure to cure Hodgkin's
disease with drugs.
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